Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma

• Sato Shuichi

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

• Muraishi Kazuhisa

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

• Tani Junichi

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

• Sasaki Yuko

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

• Tokubuchi Ichiro

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

• Tajiri Yuji

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

• Yamada Kentaro

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

• Suekane Shigetaka

  Department of Urology, Kurume University School of Medicine, Fukuoka, Japan

• Miyajima Jiro

  Department of Urology, Kurume University School of Medicine, Fukuoka, Japan

• Matsuoka Kei

  Department of Urology, Kurume University School of Medicine, Fukuoka, Japan

• Hiromatsu Yuji

  Division of Endocrinology and Metabolism, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan

抄録

Sunitinib is a multi-targeted tyrosine kinase inhibitor that is effective for advanced renal cell carcinoma. However, sunitinib often causes hypothyroidism. In this study, we report eight cases with thyroid dysfunction that occurred during sunitinib treatment for advanced renal cell carcinoma. In seven cases, mild hypothyroidism developed early in the first treatment cycle, and recovered spontaneously. Transient hyperthyroidism was observed during the second or third treatment cycles and was preceded by a rapid increase in thyroglobulin levels. ^99mTc scintigraphy in the hyperthyroid state showed decreased thyroidal uptake of ^99mTcO₄^-, suggesting destructive thyroiditis. Hypothyroidism subsequently developed, requiring levothyroxine replacement therapy. Ultrasonography showed a hypoechogenic pattern of the parenchyma and decreased intrathyroidal blood flow. The thyroid glands ultimately became atrophic, which may progress to permanent hypothyroidism. These findings suggest that sunitinib-induced hypothyroidism may occur frequently and may be a consequence of thyroiditis with transient thyrotoxicosis. The marked decrease in thyroid size due to reduced capillary blood flow induced by VEGF receptor inhibition may cause delayed and/or permanent hypothyroidism. Therefore, thyroid function should be monitored in all patients treated with sunitinib.

収録刊行物

• Endocrine Journal

  Endocrine Journal 57 (10), 873-880, 2010

  一般社団法人 日本内分泌学会

キーワード

• Hypothyroidism
• Renal cell carcinoma
• Sunitinib
• Thyrotoxicosis

詳細情報

• CRID: 1390282681274447872
• NII論文ID: 10029586528
• NII論文ID: 130004443575
• NII書誌ID: AA10901436
• DOI: 10.1507/endocrj.k10e-130
• ISSN: 13484540
• ISSN: 09188959
• ISSN: http://id.crossref.org/issn/09188959
• Web Site: http://www.jstage.jst.go.jp/article/endocrj/57/10/57_K10E-130/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2011120972
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可